Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.61 EUR
Change Today -0.339 / -5.70%
Volume 0.0
EP3 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:55 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

orasure technologies inc (EP3) Snapshot

Open
€5.68
Previous Close
€5.95
Day High
€5.68
Day Low
€5.57
52 Week High
01/26/15 - €8.94
52 Week Low
06/4/14 - €4.38
Market Cap
316.6M
Average Volume 10 Days
179.6
EPS TTM
--
Shares Outstanding
56.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ORASURE TECHNOLOGIES INC (EP3)

orasure technologies inc (EP3) Related Businessweek News

No Related Businessweek News Found

orasure technologies inc (EP3) Details

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its primary products include OraQuick ADVANCE HIV-1/2, OraQuick In-Home HIV Test, OraQuick HCV, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, HEMAgen BUFFY COAT, PrepIT—MAX, OMNIgene—Gut, OMNIgene Sputum, Intercept, MICRO-PLATE DOA Assays, Intercept i2, Homogeneous DOA Assays, and professional and over-the-counter Cryosurgical Systems. In addition, the company manufactures and sells oral fluid collection devices used to collect, stabilize, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Further, it provides medical devices used for the removal of benign skin lesions by cryosurgery or freezing; various immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company sells its products to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 1979 and is based in Bethlehem, Pennsylvania.

320 Employees
Last Reported Date: 03/12/15
Founded in 1979

orasure technologies inc (EP3) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $580.1K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $455.7K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $327.6K
Principal Accounting Officer, Senior Vice Pre...
Total Annual Compensation: $261.8K
Executive Vice President of Marketing and Sal...
Total Annual Compensation: $375.8K
Compensation as of Fiscal Year 2014.

orasure technologies inc (EP3) Key Developments

OraSure Technologies, Inc. Announces Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Second Quarter of 2015

OraSure Technologies, Inc. announced consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net revenues of $27,088,000 compared with $23,537,000 for the same period a year ago. Operating loss was $291,000 compared with $5,618,000 for the same period a year ago. Income before income taxes was $118,000 compared with loss before income taxes of $5,500,000 for the same period a year ago. Net income was $113,000 or $0.00 per basic and diluted share compared with net loss of $5,631,000 or $0.10 per basic and diluted share for the same period a year ago. Capital expenditures was $437,000 compared with $647,000 for the same period a year ago. The increases in revenues were partially offset by lower sales of the Company's cryosurgical systems, OraQuick® professional HIV and OraQuick® In-Home HIV products. The company provided earnings guidance for the second quarter of 2015. The company expects consolidated net revenues to range from $29.0 to $29.5 million and is projecting consolidated net income of approximately $0.00 to $0.01 per share for the second quarter of 2015.

OraSure Technologies Seeks Acquisitions

OraSure Technologies, Inc. (NasdaqGS:OSUR) is looking for acquisition. Doug Michels, President and Chief Executive Officer of OraSure Technologies states, "There are some very interesting opportunities out there, to be honest, Mark and we're excited. So, it doesn't mean that everything is perfect but we have seen a number of different interesting opportunities. They are as we discussed previously more in the molecular diagnostic space and so it would be somewhat adjunctive to the DNA Genotek activity. We want to look at opportunities that are not research projects, so more towards commercialized opportunities or near commercialized opportunities that are not going to push us backward away from our goal of profitability for 2015. And so we continue to work very diligently but maintaining our discipline and making sure that we hit the criteria while bringing in hopefully products and technologies or companies that would be complementary to what we are doing."

OraSure Technologies, Inc. to Report Q1, 2015 Results on May 06, 2015

OraSure Technologies, Inc. announced that they will report Q1, 2015 results at 4:00 PM, US Eastern Standard Time on May 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EP3:GR €5.61 EUR -0.339

EP3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akers Biosciences Inc $4.39 USD +0.095
Chembio Diagnostics Inc $4.50 USD -0.01
Nymox Pharmaceutical Corp $1.55 USD +0.01
Pernix Therapeutics Holdings Inc $6.37 USD +0.24
Quidel Corp $21.67 USD -0.57
View Industry Companies
 

Industry Analysis

EP3

Industry Average

Valuation EP3 Industry Range
Price/Earnings 100.0x
Price/Sales 3.2x
Price/Book 2.3x
Price/Cash Flow 315.0x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORASURE TECHNOLOGIES INC, please visit www.orasure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.